E7449: A dual inhibitor of PARP1/2 and tankyrase1/2 inhibits growth of DNA repair deficient tumors and antagonizes Wnt signaling

Oncotarget

Volumn 6, Issue 38, 2015, Pages 41307-41323

  McGonigle, Sharon ^a   Chen, Zhihong ^a   Wu, Jiayi ^a   Chang, Paul ^b   Kolber Simonds, Donna ^a   Ackermann, Karen ^a   Twine, Natalie C ^a   Shie, Jue Lon ^a   Miu, Jingzang Tao ^a,c   Huang, Kuan Chun ^a   Moniz, George A ^a,d   Nomoto, Kenichi ^a  

^a EISAI INC   (United States)

^b MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^c MODERNA THERAPEUTICS   (United States)

^d BIOGEN   (United States)

Author keywords

E7449; Inhibitor; PARP; Tankyrase; Wnt

Indexed keywords

7,8 DIHYDRO 2 [4 (TRIFLUOROMETHYL)PHENYL] 5H THIOPYRANO[4,3 D]PYRIMIDIN 4 OL; 8 (ISOINDOLIN 2 YLMETHYL) 2,9 DIHYDRO 3H PYRIDAZINO[3,4,5 DE]QUINAZOLIN 3 ONE; AXIN; AXIN2 PROTEIN; BETA CATENIN; BRCA1 PROTEIN; CARBOPLATIN; CYCLIN D1; E 6201; MITOGEN ACTIVATED PROTEIN KINASE KINASE INHIBITOR; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 2; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; OLAPARIB; TANKYRASE; TANKYRASE 1; TANKYRASE 2; TEMOZOLOMIDE; TUBULIN; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; DACARBAZINE; DNA BINDING PROTEIN; E7449 COMPOUND; ISOQUINOLINE DERIVATIVE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PARP2 PROTEIN, HUMAN; PARPBP PROTEIN, HUMAN; QUINAZOLINONE DERIVATIVE; TNKS PROTEIN, HUMAN; TNKS2 PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; BREAST CANCER; CANCER INHIBITION; CONTROLLED STUDY; DNA REPAIR; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG POTENTIATION; DRUG SENSITIVITY; DRUG STRUCTURE; FEMALE; GENE EXPRESSION; HAIR GROWTH; HOMOLOGOUS RECOMBINATION; HUMAN; HUMAN CELL; IC50; LUNG CANCER; MELANOMA B16; MOUSE; NONHUMAN; PHARMACODYNAMICS; SINGLE DRUG DOSE; TUMOR SUPPRESSOR GENE; TUMOR XENOGRAFT; WEIGHT REDUCTION; WNT SIGNALING PATHWAY; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; CELL PROLIFERATION; CHEMISTRY; DRUG EFFECTS; DRUG SCREENING; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; NEOPLASMS; NEOPLASMS, EXPERIMENTAL; NUDE MOUSE; PATHOLOGY; PROCEDURES; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCID MOUSE; TUMOR CELL LINE; TUMOR VOLUME; WESTERN BLOTTING;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLOTTING, WESTERN; CARBOPLATIN; CELL LINE, TUMOR; CELL PROLIFERATION; DACARBAZINE; DNA REPAIR; DNA-BINDING PROTEINS; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; ISOQUINOLINES; MICE, INBRED C57BL; MICE, NUDE; MICE, SCID; NEOPLASMS; NEOPLASMS, EXPERIMENTAL; POLY(ADP-RIBOSE) POLYMERASE INHIBITORS; POLY(ADP-RIBOSE) POLYMERASES; QUINAZOLINONES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TANKYRASES; TUMOR BURDEN; WNT SIGNALING PATHWAY; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84951206196     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.5846     Document Type: Article

References (55)

1. Amé J-C, Spenlehauer C, de Murcia G. The PARP superfamily. BioEssays. 2004; 26:882-93.
2. Vyas S, Matic I, Uchima L, Rood J, Zaja R, Hay RT, Ahel I, Chang P. Family-wide analysis of poly(ADP-ribose) polymerase activity. Nat Comm. 2014; 5:4426.
3. Kleine H, Poreba E, Lesniewicz K, Hassa PO, Hottiger MO, Litchfield DW, Shilton BH, Lüscher B. Substrate-assisted catalysis by PARP10 limits its activity to mono-ADP-ribosylation. Mol Cell. 2008; 32:57-69.
4. D'Amours D, Desnoyers S, D'Silva I, Poirier GG. Poly(ADP-ribosyl)ation reactions in the regulation of nuclear functions. Biochem J. 1999; 342:249-68.
5. Miwa M, Saikawa N, Yamaizumit Z, Nishimurat S, Sugimura T. Structure of poly(adenosine diphosphate ribose): Identification of 2'-[1"-ribosyl-2"-(or 3"-)(1"'-ribosyl)] adenosine-5', 5", 5"'-tris(phosphate) as a branch linkage. PNAS. 1979; 76:595-99.
6. Leung AK. Poly(ADP-ribose): An organizer of cellular architecture. J Cell Biol. 2014; 205:613-19.
7. Leine H, Lüscher B. Learning how to read ADPribosylation. Cell 2009; 139:17-19.
8. Schreiber V, Dantzer F, Amé J-C, de Murcia G. Poly(ADPribose): novel functions for an old molecule. Nat Revs Mol Cell Biol. 2006; 7:517-28.
9. Schiewer MJ, Knudsen KE. Transcriptional roles of PARP1 in cancer. Mol Cancer Res. 2014; 12:1069-80.
10. Leung AKL, Vyas S, Rood JE, Bhutkar A, Sharp PA, Chang P. Poly(ADP-ribose) regulates stress responses and microRNA activity in the cytoplasm. Mol Cell. 2011; 42:489-99.
11. Jwa M, Chang P. PARP16 is a tail-anchored endoplasmic reticulum protein required for the PERK-and IRE1a-mediated unfolded protein response. Nat Cell Biol. 2012; 14:1223-30.
12. Yamada M, Miwa M, Sugimura T. Studies on poly(adenosine diphosphate-ribose). X. Properties of a partially purified poly(adenosine diphosphate-ribose) polymerase. Arch Biochem Biophys. 1971; 146:579-86.
13. Okayama H, Edson CM, Fukushima M, Ueda K, Hayaishi O. Purification and properties of poly(adenosine diphosphate ribose) synthetase. J Biol Chem. 1977; 252:7000-5.
14. Curtin NJ, Szabo C. Therapeutic applications of PARP inhibitors: Anticancer therapy and beyond. Mol Aspects Med. 2013; 34:1217-56.
15. Lupo B, Trusolino L. Inhibition of poly(ADP-ribosyl) ation in cancer: Old and new paradigms revisited. Biochim Biophys Acta. 2014; 1846:201-15.
16. Shieh WM, Amé J-C, Wilson MV, Wang Z-Q, Koh DW, Jacobson MK, Jacobson EL. Poly(ADP-ribose) polymerase null mouse cells synthesize ADP-ribose polymers. J Biol Chem. 1998; 273:30069-72.
17. De Lorenzo SB, Patel AG, Hurley RM, Kaufmann SH. The elephant and the blind men: making sense of PARP inhibitors in homologous recombination deficient tumor cells. Front Oncol. 2013; 3:228.
18. Farmer H, McCabe N, Lord CJ, Tutt ANJ, Johnson DA, Richardson TB, Santarosa M, Dillon KJ, Hickson I, Knights C, Martin NMB, Jackson SP, Smith GCM, Ashworth A. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature. 2005; 434:917-21.
19. Bryant HE, Schultz N, Thomas HW, Parker KM, Flower D, Lopez E, Kyle S, Meuth M, Curtin NJ, Helleday T. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature. 2005; 434:913-17.
20. Durkacz BW, Omidiji O, Gray DA, Shall S. (ADP-ribose)n participates in DNA excision repair. Nature. 1980; 283: 593-96.
21. Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M, Mortimer P, Swaisland H, Lau A, O'Connor MJ, Ashworth A, Carmichael J, Kaye SB, et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med. 2009; 361:123-34.
22. Tutt A, Robson M, Garber JE, Domchek SM, Audeh MW, Weitzel JN, Friedlander M, Arun B, Loman N, Schmutzler RK, Wardley A, Mitchell G, Earl H, et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet. 2010; 376:235-44.
23. Audeh MW, Carmichael J, Penson RT, Friedlander M, Powell B, Bell-McGuinn KM, Scott C, Weitzel JN, Oaknin A, Loman N, Lu K, Schmutzler RK, Matulonis U, et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet. 2010; 376:245-51.
24. Sandhu SK, Schelman WR, Wilding G, Moreno V, Baird RD, Miranda S, Hylands L, Riisnaes R, Forster M, Omlin A, Kreischer N, Thway K, Gevensleben H, et al. The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial. Lancet Oncol. 2013; 14:882-92.
25. Riffell JL, Lord CJ, Ashworth A. Tankyrase-targeted therapeutics: expanding opportunities in the PARP family. Nat Rev Drug Discov. 2012; 11:923-36.
26. Lehtiö L, Chi N-W, Krauss S. Tankyrases as drug targets. FEBS J. 2013; 280:3576-93.
27. Chiang YJ, Hsiao SJ, Yver D, Cushman SW, Tessarollo L, Smith S, et al. Tankyrase 1 and tankyrase 2 are essential but redundant for mouse embryonic development. PLoS One. 2008; 3:e2639.
28. Ménissier de Murcia J, Ricoul M, Tartier L, Niedergang C, Huber A, Dantzer F, Schreiber V, Amé J-C, Dierich A, LeMeur M, Sabatier L, Chambon P, deMurcia G. Functional interaction between PARP-1 and PARP-2 in chromosome stability and embryonic development in mouse. EMBO J. 2003; 22:2255-63.
29. Huang S-MA, Mishina YM, Liu S, Cheung A, Stegmeier F, Michaud GA, Charlat O, Wiellette E, Zhang Y, Wiessner S, Hild M, Shi X, Wilson CJ, et al. Tankyrase inhibition stabilizes axin and antagonizes Wnt signaling. Nature. 2009; 461:614-20.
30. Plummer R, Dua D, Cresti N, Suder A, Drew Y, Prathapan V, Stephens P, Thornton J, Ink B, Lee L, Matijevic M, McGrath S, Sarker D. Phase 1 study of the PARP inhibitor E7449 as a single agent in patients with advanced solid tumors or B-cell lymphoma. Annals Oncol. 2014; 25:iv146-iv164.
31. McGonigle S, Chen Z, Wu J, Kolber-Simonds D, McGrath S, TenDyke K, Wang Z, Nomoto K. E7449, a potent inhibitior of PARP1 and 2, is active in acute myeloid leukemia. Cancer Res. 2013; 73:3323.
32. Menear KA, Adcock C, Boulter R, Cockroft XL, Copsey L, Cranston A, Dillon KJ, Drzewiecki J, Garman S, Gomez S, Javaid H, Kerrigan F, Knights C, et al. 4-[3-(4-cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2-Hphthalazin-1-one: a novel bioavailable inhibitor of poly(ADP-ribose) polymerase-1. J Med Chem. 2008; 51:6581-91.
33. Kedar PS, Stefanick DF, Horton JK, Wilson SH. Increased PARP-1 association with DNA in alkylation damaged, PARP-inhibited mouse fibroblasts. Mol Cancer Res. 2012; 10:360-68.
34. Helleday T. The underlying mechanism for the PARP and BRCA synthetic lethality: Clearing up the misunderstandings. Mol Oncol. 2011; 5:387-93.
35. Murai J, Huang SN, Das BB, Renaud A, Zhang Y, Doroshow JH, Ji J, Takeda S, Pommier Y. Trapping of PARP1 and PARP2 by clinical PARP inhibitors. Cancer Res. 2012; 72:5588-99.
36. Ridpath JR, Takeda S, Swenberg JA, Nakamura J. Convenient, multi-well plate-based DNA damage response analysis using DT40 mutants is applicable to a highthroughput genotoxicity assay with characterization of modes of action. Environ Mol Mutagen. 2011; 52:153-160.
37. Palma JP, Wang Y-C, Rodriguez LE, Montgomery D, Ellis PA, Bukofzer G, Niquette A, Liu X, Shi Y, Lasko L, Zhu G-D, Penning TD, Giranda VL, et al. ABT-888 confers broad in vivo activity in combination with temozolomide in diverse tumors. Clin Cancer Res. 2009; 15:7277-90.
38. Plummer R, Lorigan P, Steven N, Scott L, Middleton MR, Wilson RH, Mulligan E, Curtin N, Wang D, Dewji R, Abbattista A, Gallo J, Calvert H. A phase ll study of the potent PARP inhibitor, Rucaparib (PF-01367338, AG014699), with temozolomide in patients with metastatic melanoma demonstrating evidence of chemopotentiation. Cancer Chemother Pharmacol. 2013; 71:1191-99.
39. Drew Y, Mulligan EA, Vong W-T, Thomas HD, Kahn S, Kyle S, Mukhopadhyay A, Los G, Hostomsky Z, Plummer ER, Edmondson RJ, Curtin NJ. Therapeutic potential of poly(ADP-ribose) polymerase inhibitor AG014699 in human cancers with mutated or methylated BRCA1 or BRCA2. J Natl Cancer Ins. 2010; 103:334-46.
40. Kinders RJ, Hollingshead M, Khin S, Rubinstein L, Tomaszewski JE, Doroshow JH, Parchment RE. Preclinical modeling of a phase 0 clinical trial: qualification of a pharmacodynamic assay of poly(ADP-ribose) polymerase in tumor biopsies of mouse xenografts. Clin. Cancer Res. 2008; 14:6877-85.
41. Aguilar-Quesada R, Munoz-Gàmez JA, Martín-Oliva D, Peralta-Leal A, Quiles-Pérez R, Rodríguez-Vargas JM, Ruiz de Almodóvar M, Conde C, Ruiz-Extremera A, Oliver FJ. Modulation of transcription by PARP-1: Consequences in carcinogenesis and inflammation. Curr Med Chem. 2007; 14:1179-87.
42. Kishimoto J, Burgeson RE, Morgan BA. Wnt signaling maintains the hair-inducing activity of the dermal papilla. Genes Dev. 2000; 14:1181-85.
43. Blagodatski A, Poteryaev D, Katanaev VL. Targeting the Wnt pathways for therapies. Mol Cell Ther. 2014; 2:28-43.
44. Lei M-X, Chuong C-M, Widelitz RB. Tuning Wnt signals for more or fewer hairs. J Invest Dermatol. 2013; 133:7-9.
45. Tsukamoto AS, Grosschedl R, Guzman RC, Parslow T, Varmus HE. Expression of the int-1 gene in transgenic mice is associated with mammary gland hyperplasia and adenocarcinomas in male and female mice. Cell. 1988; 55:619-625.
46. Jones P, Altamura S, Boueres J, Ferrigno F, Fonsi M, Giomini C, Lamartina S, Monteagudo E, Ontoria JM, Orsale MV, Palumbi MC, Pesci S, Roscilli G, et al. Discovery of 2-(4-[(3S)-piperidin-3-yl]phenyl)-2H-indazole-7-carboxamide (MK-4827): a novel oral poly(ADP-ribose)polymerase (PARP) inhibitor efficacious in BRCA-1 and-2 mutant tumors. J Med Chem. 2009; 52:7170-85.
47. Shen Y, Rehman FL, Feng Y, Boshuizen J, Bajrami I, Elliot R, Wang B, Lord CJ, Post LE, Ashworth A. BMN 673, a novel and highly potent PARP1/2 inhibitor for the treatment of human cancers with DNA repair deficiency. Clin Cancer Res. 2013; 19:1-13.
48. Wahlberg E, Karlberg T, Kouznetsova E, Markova N, Macchiarulo A, Thorsell A-G, Pol E, Frostell Å, Ekblad T, Öncü D, Kull B, Robertson GM, Pellicciari R, et al. Familywide chemical profiling and structural analysis of PARP and tankyrase inhibitors. Nature Biotech. 2012; 30:283-88.
49. Li VSW, Ng SS, Boersema PJ, Low TY, Karthaus WR, Gerlach JP, Mohammed S, Heck AJR, Maurice MM, Mahmoudi T, Clevers H. Wnt signaling through inhibition of β-catenin degradation in an intact axin1 complex. Cell. 2012; 149:1245-56.
50. Lau T, Chan E, Callow M, Waaler J, Boggs J, Blake RA, Magnuson S, Sambrone A, Schutten M, Firestein R, Machon O, Korinek V, Choo E, et al. A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth. Cancer Res. 2013; 73:3132-44.
51. Pinto D, Gregorieff A, Begthel H, Clevers H. Canonical Wnt signals are essential for homeostasis of the intestinal epithelium. Genes & Dev. 2003; 17:1709-13.
52. Kuhnert F, Davis CR, Wang H-T, Chu P, Lee M, Yuan J, Nusse R, Kuo CJ. Essential requirement for Wnt signaling in proliferation of adult small intestine and colon revealed by adenoviral expression of Dickkopf-1. PNAS. 2004; 101:266-71.
53. Spreafico A, Tentler JJ, Pitts TM, Tan AC, Gregory MA, Arcaroli JJ, Klauck PJ, McManus MC, Hansen RJ, Kim J, Micel LN, Selby HM, Newton TP, et al. Rational combination of a MEK inhibitor, Selumetinib, and the Wnt/calcium pathway modulator, Cyclosporin A, in preclinical models of colorectal cancer. Clin Cancer Res. 2013; 19:4149-62.
54. Schoumacher M, Hurov KE, Lehár J, Yan-Neale Y, Mishina Y, Sonkin D, Korn JM, Flemming D, Jones MD, Antonakos B, Cooke VG, Steiger J, Ledell J, et al. Inhibiting tankyrases sensitizes KRAS-mutant cancer cells to MEK inhibitors via FGFR2 feedback signaling. Cancer Res. 2014; 74:3294-305.
55. Casás-Selves M, Kim J, Zhang Z, Helfrich BA, Gao D, Porter CC, Scarborough HA, Bunn PA Jr, Chan DC, Tan AC, DeGregori J. Tankyrase and the canonical Wnt pathway protect lung cancer cells from EGFR inhibition. Cancer Res. 2012; 72:4154-64.